Background and Purpose-Identification of single-nucleotide polymorphisms (SNPs) associated with increased risk of new intracranial hemorrhage (ICH) after brain arteriovenous malformation (BAVM) diagnosis would facilitate risk stratification and identify potential targets for therapeutic intervention. Methods-Patients with BAVM were longitudinally followed. Primary outcome was new ICH after diagnosis; censoring events were last follow-up or any BAVM treatment. We genotyped 4 promoter SNPs in 2 inflammatory cytokine genes: interleukin-6 (IL-6 -174GϾC; IL-6 -572GϾC) and tumor necrosis factor-␣ (TNF-␣-238GϾA; TNF-␣-308GϾA). Association of genotype with risk of new ICH was screened using 2 ; SNPs associated with new ICH were further characterized using Cox proportional hazards. Results-We genotyped 280 patients (50% female; 59% white, meanϮSD age at diagnosis 37Ϯ17 years; 40% presenting with ICH). TNF-␣-238GϾA was associated with increased risk of new ICH after diagnosis ( 2 ; Pϭ0.003). After adjusting for age, race/ethnicity, and clinical presentation, the risk of new ICH was increased for patients with TNF-␣-238 AG genotype (hazard ratio, 4.01; Pϭ0.015). 
W
e previously reported on genes implicated in inflammatory and angiogenic pathways and found an interleukin-6 (IL-6) single-nucleotide polymorphism (SNP), IL-6 -174GϾC, was associated with presenting intracranial hemorrhage (ICH) at brain arteriovenous malformation (BAVM) diagnosis; a tumor necrosis factor-␣ (TNF-␣) SNP, TNF-␣-308GϾA, showed a similar trend. 1 In this study, we sought to examine whether promoter polymorphisms in these 2 genes (IL-6: -174GϾC, -572GϾC; TNF-␣: -238GϾA, -308GϾA) were associated with risk of new ICH after diagnosis in the natural course of BAVMs.
Materials and Methods
With informed consent, we recruited BAVM patients at the University of California San Francisco (UCSF) 1 or at Kaiser Permanente Northern California (KPNC) 2 and classified them using standardized guidelines. 3 We genotyped 4 polymorphisms by template-directed dye-terminator incorporation assay with fluorescence polarization detection. 1 The primary outcome was occurrence of new ICH (symptomatic new hemorrhage with intracranial blood on computed tomography or MRI) after initial presentation, before any treatment.
Association of genotype with risk of new ICH after diagnosis was screened ( 2 tests; t tests). SNPs found to have association with new ICH that survived Bonferroni correction (Pϭ0.0125) were selected for survival analyses (Cox regression; Kaplan-Meier).
The period at risk was defined from date of BAVM diagnosis to date of an event (ie, onset of new [first subsequent] ICH) or censoring attributable either to initiation of first BAVM treatment (surgery, embolization, or radiosurgery) or loss to follow-up (using date of last available follow-up), whichever occurred first.
The predictors in our multivariate model were chosen based on their clinical/statistical importance to the outcome in an attempt to achieve maximum parsimony. The predictors included genotype, age at diagnosis (years), race/ethnicity (white versus nonwhite) and initial presentation (presenting ICH versus nonhemorrhagic presentation at diagnosis); their effects were reported as hazard ratios (HRs) and CIs. 
Results
We genotyped 280 patients (Table 1) ; 189 were evaluated at UCSF and 91 at KPNC. As reported previously, 1 patients homozygous for IL-6 -174G had a greater risk of presenting with ICH than IL-6 -174C carriers (univariate logistic regression analysis; HR, 2.00 [CI, 1.20 to 3.35]; Pϭ0.008). Neither the more distal IL-6 -572GϾC SNP nor the 2 TNF-␣ SNPs were associated with ICH presentation.
In contrast, only the TNF-␣ promoter SNP TNF-␣-238GϾA was associated with increased risk of new ICH after diagnosis (meanϮSD follow-up 2.7Ϯ6.7 years). Overall, 224 (80.0%) cases were followed until censoring treatment (74 surgery, 107 embolization, and 43 radiosurgery), and 38 (13.6%) were untreated at last follow-up. New ICH in the natural course after diagnosis occurred in 18 (6.4%) patients and was associated with the AG genotype of TNF-␣-238GϾA ( 2 ; Pϭ0.003); this association survived correction for multiple testing.
TNF-␣-238GϾA was selected for further analysis to estimate prediction of BAVM hemorrhage risk ( Results were unaffected by including center of ascertainment (UCSF versus KPNC) as a factor in the models.
TNF-␣-238 AG genotype conferred similar magnitude of risk in subset analysis within the major ethnic group (whites) and in stratified analysis irrespective of presenting ICH versus non-ICH presentation (data not shown). Haplotype analysis was performed for TNF-␣ and IL-6 genes; results were consistent with single-SNP results but did not contribute additional information (data not shown).
Discussion
This study demonstrates the first evidence of an association between genotype and risk of new ICH in the natural course of BAVMs. The AG genotype of the TNF-␣-238GϾA promoter polymorphism was associated with a 4-fold increase in risk of new ICH. This finding further implicates inflammatory processes in the pathogenesis of vessel rupture. TNF-␣ is a proinflammatory and immunomodulatory cytokine implicated in inflammatory conditions that involve proteolytic processes. 4 TNF-␣-238 AG genotype has been associated with a high cytokine expressor phenotype. 5 As an upstream modulator for many inflammatory cytokines and proteolytic enzymes, TNF-␣ induces IL-6 and matrix metalloproteinases, a family of proteolytic enzymes that degrade extracellular matrix around blood vessels and damage endothelial cells, which could result in destabilization and potential weakening of the vessel wall, passive dilation, and rupture. 6 Surgical BAVM specimens display elevated matrix metalloproteinase expression. 6 IL-6 expression appears to be increased as well and is associated with IL-6 -174 GG genotype. 7 Although these observations suggest a common pathway whereby genetic variation in IL-6 and TNF-␣ influences hemorrhagic risk, it remains unclear why only the IL-6 -174 GG genotype was associated with hemorrhagic presentation at diagnosis, whereas the current study only implicates TNF-␣-238 AG genotype in increased risk of new ICH in the natural course of disease after presentation.
A limitation of the current study is that the results depend on events in a small subset of our patients, which makes it difficult to assess more complicated models and fully explore possible confounders. Another consequence is a wide CI for the HR for TNF-␣ in Table 2 (1.31-12.29), although this does bound the HR to be Ն1.31. Nevertheless, we believe these findings indicate that the role of inflammatory cytokines in the pathogenesis of BAVM hemorrhage merits further study. 
